S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
The 3-Stock Retirement Blueprint (Ad)
Denmark says Nord Stream 1 pipelines stop leaking
UK government drops key part of tax cuts package that sparked market turmoil, sent pound plunging
The 3-Stock Retirement Blueprint (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
The 3-Stock Retirement Blueprint (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Voter apathy in Bulgaria opens door for pro-Russia groups
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
The 3-Stock Retirement Blueprint (Ad)
Denmark says Nord Stream 1 pipelines stop leaking
UK government drops key part of tax cuts package that sparked market turmoil, sent pound plunging
The 3-Stock Retirement Blueprint (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
The 3-Stock Retirement Blueprint (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Voter apathy in Bulgaria opens door for pro-Russia groups
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
The 3-Stock Retirement Blueprint (Ad)
Denmark says Nord Stream 1 pipelines stop leaking
UK government drops key part of tax cuts package that sparked market turmoil, sent pound plunging
The 3-Stock Retirement Blueprint (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
The 3-Stock Retirement Blueprint (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Voter apathy in Bulgaria opens door for pro-Russia groups
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
The 3-Stock Retirement Blueprint (Ad)
Denmark says Nord Stream 1 pipelines stop leaking
UK government drops key part of tax cuts package that sparked market turmoil, sent pound plunging
The 3-Stock Retirement Blueprint (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
The 3-Stock Retirement Blueprint (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Voter apathy in Bulgaria opens door for pro-Russia groups
NASDAQ:SRNE

Sorrento Therapeutics - SRNE Stock Forecast, Price & News

$1.57
-0.01 (-0.63%)
(As of 09/30/2022 09:02 PM ET)
Add
Compare
Today's Range
$1.54
$1.66
50-Day Range
$1.51
$2.77
52-Week Range
$1.15
$7.74
Volume
3.36 million shs
Average Volume
9.18 million shs
Market Capitalization
$706.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.00

Sorrento Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,173.9% Upside
$20.00 Price Target
Short Interest
Bearish
12.56% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.36
Upright™ Environmental Score
News Sentiment
0.33mentions of Sorrento Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$45,777 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.94) to ($0.62) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.13 out of 5 stars

Medical Sector

573rd out of 1,095 stocks

Biological Products, Except Diagnostic Industry

95th out of 171 stocks

SRNE stock logo

About Sorrento Therapeutics (NASDAQ:SRNE) Stock

Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 94 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California.

Receive SRNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sorrento Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SRNE Stock News Headlines

3 Biotech Stocks Gaining Momentum (SRNE)
The headlines have been particularly good for a trio of small cap biotechs and it appears the momentum may have staying power.
SRNE Sorrento Therapeutics, Inc.
Why Sorrento Therapeutics Stock Is Marching Higher Today
Why Sorrento Therapeutics Stock Is Popping Today
See More Headlines
Receive SRNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sorrento Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SRNE Company Calendar

Today
10/02/2022
Next Earnings (Estimated)
11/04/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SRNE
Employees
799
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$20.00
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+1,173.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-428,330,000.00
Net Margins
-952.63%
Pretax Margin
-1,013.72%

Debt

Sales & Book Value

Annual Sales
$52.90 million
Book Value
$0.26 per share

Miscellaneous

Free Float
435,104,000
Market Cap
$706.42 million
Optionable
Optionable
Beta
2.27

Key Executives

  • Dr. Henry H. Ji Ph.D. (Age 58)
    Chairman, Pres & CEO
    Comp: $1.69M
  • Ms. Elizabeth Adkins Czerepak M.B.A. (Age 66)
    Exec. VP, CFO & Chief Bus. Officer
    Comp: $8.12k
  • Mr. Brian Cooley
    Sr. VP of Corp. Communications & Lymphatic Drug Devel. BU
  • Mr. William J. Farley B.Sc. (Age 66)
    VP of Sales & Bus. Devel.
  • Dr. Michael A. Royal (Age 68)
    SVP & Chief Medical Officer
  • Dr. Alexis Nahama D.V.M.
    Sr. VP of Neurotherapeutics BU
  • Dr. Mark R. Brunswick
    Sr. VP of Regulatory Affairs
  • Dr. Shawn Sahebi Ph.D.
    Sr. VP of Commercial Operations
  • Dr. Robert D. Allen Ph.D.
    Sr. VP of R&D
  • Dr. Xiao Xu M.D.
    Pres of ACEA













SRNE Stock - Frequently Asked Questions

Should I buy or sell Sorrento Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sorrento Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SRNE shares.
View SRNE analyst ratings
or view top-rated stocks.

What is Sorrento Therapeutics' stock price forecast for 2022?

1 brokerages have issued 12-month price objectives for Sorrento Therapeutics' shares. Their SRNE share price forecasts range from $20.00 to $20.00. On average, they anticipate the company's stock price to reach $20.00 in the next twelve months. This suggests a possible upside of 1,173.9% from the stock's current price.
View analysts price targets for SRNE
or view top-rated stocks among Wall Street analysts.

How have SRNE shares performed in 2022?

Sorrento Therapeutics' stock was trading at $4.65 at the beginning of 2022. Since then, SRNE stock has decreased by 66.2% and is now trading at $1.57.
View the best growth stocks for 2022 here
.

When is Sorrento Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, November 4th 2022.
View our SRNE earnings forecast
.

What other stocks do shareholders of Sorrento Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sorrento Therapeutics investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Vaxart (VXRT), Advanced Micro Devices (AMD), Moderna (MRNA), NVIDIA (NVDA), ADMA Biologics (ADMA), Tesla (TSLA), Dynavax Technologies (DVAX) and NIO (NIO).

What is Sorrento Therapeutics' stock symbol?

Sorrento Therapeutics trades on the NASDAQ under the ticker symbol "SRNE."

How do I buy shares of Sorrento Therapeutics?

Shares of SRNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sorrento Therapeutics' stock price today?

One share of SRNE stock can currently be purchased for approximately $1.57.

How much money does Sorrento Therapeutics make?

Sorrento Therapeutics (NASDAQ:SRNE) has a market capitalization of $706.42 million and generates $52.90 million in revenue each year.

How many employees does Sorrento Therapeutics have?

The company employs 799 workers across the globe.

How can I contact Sorrento Therapeutics?

Sorrento Therapeutics' mailing address is 4955 DIRECTORS PLACE, SAN DIEGO CA, 92121. The official website for the company is www.sorrentotherapeutics.com. The biopharmaceutical company can be reached via phone at (858) 203-4100, via email at investors@sorrentotherapeutics.com, or via fax at 858-210-3759.

This page (NASDAQ:SRNE) was last updated on 10/3/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.